New CEO in Navamedic ASA
Olof Milveden is appointed new CEO of Navamedic ASA. Olof Milveden has 27 years of experience from the pharma/health care industry. His last position has been that of CEO and Cluster Head Nordic in Sandoz A/S (Denmark). He has working experience from Europe, Asia, Africa and USA. Previous positions have been among others; Regional Manager, Asia Pacific for Merck Pharmaceuticals, Managing Director Merck Generics Nordic, Managing Director South Africa in Merck Pharmaceuticals. He has also held a Swedish diplomatic post as the Trade commissioner to India and he has had leading positions in smaller companies such as Organon Teknika Sweden.
Olof Milveden is 56 years and from Sweden. He will have his office in Gothenburg and started in the position as CEO on 4 May.
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
List_of_subjects_in_Gray's_Anatomy:_Alphabetical:_F

Nanosafety research without animal experiments - Risk analyses for nanoparticles
OctoPlus gains full rights to PolyActive drug delivery technology from IsoTis
Singapore's first commercial developer of molecular diagnostic assays opens operations

Triacle Biocomputing - Oulu, Finland
Vetter Development Service Chicago is now ready for realizing clinical syringe projects
BioXell announces positive Phase IIb results for Elocalcitol in Benign Prostatic Hyperplasia - Primary endpoint met - Elocalcitol highly effective in arresting prostate growth
